DE69918404D1 - Aminophenoxyessigsäure derivate als neuroschützende mittel - Google Patents

Aminophenoxyessigsäure derivate als neuroschützende mittel

Info

Publication number
DE69918404D1
DE69918404D1 DE69918404T DE69918404T DE69918404D1 DE 69918404 D1 DE69918404 D1 DE 69918404D1 DE 69918404 T DE69918404 T DE 69918404T DE 69918404 T DE69918404 T DE 69918404T DE 69918404 D1 DE69918404 D1 DE 69918404D1
Authority
DE
Germany
Prior art keywords
group
acid derivatives
protective agent
aminophenoxyacetic acid
neuro protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918404T
Other languages
English (en)
Other versions
DE69918404T2 (de
Inventor
Hirokazu Annoura
Naohiro Takemoto
Hiroshi Uramoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
Original Assignee
Daiichi Suntory Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Suntory Pharma Co Ltd filed Critical Daiichi Suntory Pharma Co Ltd
Application granted granted Critical
Publication of DE69918404D1 publication Critical patent/DE69918404D1/de
Publication of DE69918404T2 publication Critical patent/DE69918404T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69918404T 1998-10-16 1999-10-14 Aminophenoxyessigsäure derivate als neuroschützende mittel Expired - Lifetime DE69918404T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP29488698 1998-10-16
JP29488698 1998-10-16
PCT/JP1999/005658 WO2000023076A1 (en) 1998-10-16 1999-10-14 Aminophenoxyacetic acid derivatives as neuroprotectants

Publications (2)

Publication Number Publication Date
DE69918404D1 true DE69918404D1 (de) 2004-08-05
DE69918404T2 DE69918404T2 (de) 2005-08-04

Family

ID=17813532

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918404T Expired - Lifetime DE69918404T2 (de) 1998-10-16 1999-10-14 Aminophenoxyessigsäure derivate als neuroschützende mittel

Country Status (12)

Country Link
US (3) US6559146B1 (de)
EP (1) EP1045693B1 (de)
JP (1) JP2002527477A (de)
KR (1) KR100676109B1 (de)
CN (1) CN1198613C (de)
AT (1) ATE270103T1 (de)
AU (1) AU762345B2 (de)
CA (1) CA2315050C (de)
DE (1) DE69918404T2 (de)
ES (1) ES2221440T3 (de)
HU (1) HUP0100819A3 (de)
WO (1) WO2000023076A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762345B2 (en) * 1998-10-16 2003-06-26 Asubio Pharma Co., Ltd. Aminophenoxyacetic acid derivatives as neuroprotectants
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
EP1263729B1 (de) 2000-03-06 2006-12-20 Acadia Pharmaceuticals Inc. Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
KR100853968B1 (ko) * 2000-04-13 2008-08-25 아스비오파마 가부시키가이샤 아미노페녹시아세트아미드 유도체 및 그를 함유하는약제학적 조성물
NZ524100A (en) * 2000-08-08 2005-01-28 Ortho Mcneil Pharm Inc 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US20030186963A1 (en) * 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
KR20050008846A (ko) 2002-06-24 2005-01-21 아카디아 파마슈티칼스 인코포레이티드 세로토닌 수용체 제제로서의 n-치환된 피페리딘 유도체
CA2512639C (en) 2003-01-16 2012-10-30 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
WO2006002361A2 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
KR101260036B1 (ko) 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 N-(4-플루오로벤질)-n-(1-메틸피페리딘-4-일)-n'-(4-(2-메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1946063A4 (de) 2005-10-05 2009-08-12 Lg Electronics Inc Verfahren und vorrichtung zur signalverarbeitung und codierungs- und decodierungsverfahren und vorrichtung dafür
KR100857118B1 (ko) 2005-10-05 2008-09-05 엘지전자 주식회사 신호 처리 방법 및 이의 장치, 그리고 인코딩 및 디코딩방법 및 이의 장치
US7752053B2 (en) 2006-01-13 2010-07-06 Lg Electronics Inc. Audio signal processing using pilot based coding
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
DK2151439T3 (en) 2007-04-27 2014-03-10 Daiichi Sankyo Co Ltd Nitrogenated AROMATIC 6-membered RINGDERIVAT, AND THIS pharmaceutical composition comprising
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP3325444B1 (de) 2015-07-20 2021-07-07 Acadia Pharmaceuticals Inc. Verfahren zur herstellung von n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy) phenylmethyl)carbamide und seinem tartrat-salt und seiner polymorphen form c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
KR20190015748A (ko) 2016-06-08 2019-02-14 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Atf4 경로 억제제로서의 화학적 화합물
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
CR20200054A (es) 2017-08-09 2020-03-21 Denali Therapeutics Inc Compuestos, composiciones y métodos
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
HUE062446T2 (hu) 2017-09-01 2023-11-28 Denali Therapeutics Inc Vegyületek, készítmények és eljárások
EP3768660A1 (de) * 2018-03-23 2021-01-27 Denali Therapeutics Inc. Modulatoren des eukaryotischen initiationsfaktors 2
EP3923935A4 (de) 2019-02-13 2022-10-26 Denali Therapeutics Inc. Verbindungen, zusammensetzungen und verfahren
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214147A (en) * 1987-08-12 1993-05-25 Elf Atochem North America, Inc. Process for preparing reactive hindered amine light stabilizers
DK662188A (da) 1987-11-27 1989-05-28 Eisai Co Ltd Cykliske aminer og farmakologiske praeparater med indhold af saadanne
DE4032766A1 (de) 1990-10-16 1992-04-30 Basf Ag Phenylpiperidinoylamine und diese enthaltende arzneimittel
IL105716A0 (en) * 1992-06-08 1993-09-22 Richter Gedeon Vegyeszet Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them
KR19990037220A (ko) * 1997-10-31 1999-05-25 타이도 나오카타 아릴아세트산 아미드 유도체 또는 그 염 및 이를 함유하는 의약
AU762345B2 (en) 1998-10-16 2003-06-26 Asubio Pharma Co., Ltd. Aminophenoxyacetic acid derivatives as neuroprotectants

Also Published As

Publication number Publication date
US20040063748A1 (en) 2004-04-01
KR20010033169A (ko) 2001-04-25
AU762345B2 (en) 2003-06-26
US6998401B2 (en) 2006-02-14
KR100676109B1 (ko) 2007-02-01
CN1198613C (zh) 2005-04-27
EP1045693A1 (de) 2000-10-25
HUP0100819A3 (en) 2002-12-28
AU6122699A (en) 2000-05-08
DE69918404T2 (de) 2005-08-04
JP2002527477A (ja) 2002-08-27
US20050245574A1 (en) 2005-11-03
CA2315050C (en) 2009-02-03
HUP0100819A2 (hu) 2001-08-28
ATE270103T1 (de) 2004-07-15
US7488738B2 (en) 2009-02-10
US6559146B1 (en) 2003-05-06
ES2221440T3 (es) 2004-12-16
EP1045693B1 (de) 2004-06-30
CN1287487A (zh) 2001-03-14
WO2000023076A1 (en) 2000-04-27
CA2315050A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
ATE270103T1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
DE60316686D1 (de) Bisarylsulfonamid-derivate und ihre verwendung für krebs therapie
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
ATE180468T1 (de) Anthranilsäure derivate
DE69811329D1 (de) Imidazolidin-4-on Derivate verwendbar als Antikrebsmittel
BR0309447A (pt) Composto, agente, processos para a preparação dos mesmos, e para o combate do crescimento de plantas indesejadas, e, uso do composto
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
ATE145906T1 (de) Benzamid-derivate
EA200601092A1 (ru) Фунгицидные смеси на основе производных карбаматов и инсектицидов
YU5199A (sh) Farmaceutski proizvodi za lečenje i sprečavanje bolesti nastalih od oštećenja vaskularnih endotelialnih ćelija
KR960706476A (ko) 인터류킨-1 활성 억제제로서의 신규한 벤젠설포닐아민 유도체(Novel benzen-esulfonylimine derivatives as inhibitors of lL-1 action)
ATE504572T1 (de) Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
DK1209166T3 (da) Hidtil ukendte A-500 359-derivater
DK0485219T3 (da) Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser
ATE123487T1 (de) Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen.
DK0514942T3 (da) Hidtil ukendte benzopyranderivater og fremgangsmåder til fremstilling deraf
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
EA200101170A1 (ru) Галоидпроизводные 9-деоксо-9а-аза-9а-гомоэритромицина а
WO2001079170A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
ATE86117T1 (de) Zusammensetzung gegen leberkrankheiten.
DE69909811D1 (de) Substituierte isoxazolylthiophenverbindungen
NO921282D0 (no) Benzotiazolderivater og deres anvendelse

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI ASUBIO PHARMA CO., LTD., TOKIO/TOKYO, JP

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASUBIO PHARMA CO., LTD., TOKYO, JP